<DOC>
	<DOCNO>NCT00558337</DOCNO>
	<brief_summary>Determine novel levodopa/carbidopa formulation result well clinical response Parkinson 's Disease patient compare reference formulation levodopa/carbidopa term motor complication , onset action response duration .</brief_summary>
	<brief_title>Efficacy , Safety , Pharmacokinetics/Pharmacodynamic Study L-Dopa/Carbidopa To Treat Parkinson 's Disease</brief_title>
	<detailed_description>Primary objective demonstrate well clinical response profile novel levodopa/carbidopa formulation vs. reference formulation levodopa/carbidopa patient Parkinson 's Disease judge motor performance describe pharmacokinetic profile novel formulation compare reference .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Clinical diagnostic Parkinson 's Disease , Hoehn Yahr Staging within 24 , LDopa therapy complication least 2years LDopa therapy Patients ability differentiate `` ON '' `` OFF '' period Patients receive stable dos LDopa 600 1600 mg/day , least 2 month prior screen visit use dose regimen high 5 time day , expect investigator 's opinion need dose modification duration study Patients present score least 2 UPDRS IVa , item 32 and/or score least 2 UPDRS IVb , item 39 , screen randomization visit base clinical record first visit daily diary card randomization time . Willing able understand sign Informed Consent form Patients diagnosis know secondary Parkinsonian syndrome , ( vascular , toxin druginduced , metabolic infectious , etc ) neurodegenerative disorder parkinsonism ( Progressive Supranuclear Palsy , Corticobasal Degeneration , Multiple System Atrophy , etc ) . Patients receive concomitant antiParkinsonian pharmacological therapy affect Ldopa dopamine metabolisom ( COMT inhibitor MAO inhibitor ) Subjects undergone prior functional neurosurgical treatment PD ( ablation Deep Brain Stimulation ) . Patient Ldopa dosage regimen great 5 time day able adapt q.i.d . regimen . Patients receive Ldopa / Decarboxylase inhibitor therapy less 2 year . Patients need nightly dose Ldopa / Decarboxylase inhibitor apart four daily dos . Any medical condition past medical history , investigator 's judgment , would increase risk exposure Ldopa / Carbidopa interfere evaluation study objective . Patients unstable clinically significant know medical illness ; cardiac , pulmonary , kidney , hepatic and/or gastrointestinal disease would , investigator 's judgment , interfere safe course study . Cognitive impaired patient , determine score less 26 MiniMental Score Status Examination . ( MMSE &lt; 26 ) . Alcohol illegal drug abuse . Pregnant lactating patient . Hypersensitivity investigational drug , base know allergy drug class . Patients take research drug last 30 day prior begin study . Blood donation , blood product , participation clinical trial serial blood withdrawal , within twelve week prior start trial , intention donate blood blood product within three month follow study completion . Patients receive following medication anticipation 7 treatmentdrug elimination halflives entry time : Dopamine D2 receptor antagonist , isoniazid , antiepileptic drug , IMAO A B , pyridoxine , ferrous salt methyldopa .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Treatment Parkinson 's Disease</keyword>
</DOC>